Retinal Vein Occlusion Pipeline Gains Momentum as 14+ Emerging Therapies Advance Across Clinical Stages | DelveInsight

Retinal Vein Occlusion companies such as Kodiak Sciences, Merck, Annexin Pharmaceutical, Kalaris Therapeutics, Perfuse Therapeutics, PulseSight Therapeutics, and others are actively transforming the therapeutic landscape through advanced retinal vascular therapies, sustained-delivery anti-VEGF platforms, bispecific antibodies, and next-generation biologics aimed at improving long-term visual outcomes and reducing treatment burden.

DelveInsight's "Retinal Vein Occlusion Pipeline Insight 2026" report provides comprehensive insights into 13+ companies and 14+ pipeline drugs within the Retinal Vein Occlusion pipeline landscape. The report offers an in-depth evaluation of pipeline drug profiles, including clinical and nonclinical stage candidates. It further provides detailed therapeutic assessment based on product type, stage of development, route of administration, and molecule type, while also highlighting inactive pipeline products and discontinued programs.

Explore the evolving Retinal Vein Occlusion therapeutic landscape and future commercial opportunities here: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Retinal Vein Occlusion Pipeline Report
• The Retinal Vein Occlusion pipeline currently includes more than 14 active therapeutic candidates across various stages of development.
• Long-acting anti-VEGF therapies and vascular stabilization approaches are emerging as major innovation areas within the pipeline landscape.
• Companies are increasingly focusing on reducing intravitreal injection frequency to improve patient adherence and treatment outcomes.
• Bispecific antibodies and recombinant fusion proteins are gaining traction due to their ability to target multiple pathological pathways simultaneously.
• Strategic mergers, acquisitions, and licensing activities continue to strengthen ophthalmology pipelines globally.
• Increasing adoption of advanced retinal imaging technologies is supporting more precise diagnosis and patient monitoring.
• Growing emphasis on personalized retinal care and durable efficacy is expected to reshape future treatment paradigms.
• The pipeline demonstrates strong diversification across biologics, monoclonal antibodies, peptides, gene therapies, and polymer-based therapeutics.
• In February 2026, Bayer receives MHRA authorisation for third retinal indication of Eylea® (aflibercept 8 mg) for treatment of retinal vein occlusion
• In August 2025, Regeneron Pharmaceuticals announced that the FDA extended the target action dates to Q4 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions, including a CMC Prior-Approval Supplement for the prefilled syringe and a supplemental BLA for macular edema following retinal vein occlusion and expanded monthly dosing across approved indications.
• In April 2025, Regeneron Pharmaceuticals announced that the FDA accepted for Priority Review its supplemental Biologics License Application for EYLEA HD® (aflibercept) Injection 8 mg. The application seeks approval for treating macular edema following retinal vein occlusion (RVO) and expanding the dosing schedule to monthly. The FDA's target action date is August 19, 2025.
• In January 2025, AI Optics Inc. received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system. Designed for point-of-care use, it offers non-dilated imaging and is portable, affordable, and suitable for primary care, optometry, retail clinics, and home health settings.
• In Dec 2024, Regeneron Pharmaceuticals announced that the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusions.

Request for free sample report now: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Understanding Retinal Vein Occlusion: A Major Cause of Vision Loss Worldwide
Retinal Vein Occlusion (RVO) is a serious retinal vascular disorder characterized by blockage of the veins responsible for draining blood from the retina. The obstruction is commonly caused by thrombus formation, resulting in impaired blood circulation, retinal ischemia, hemorrhage, and fluid accumulation within retinal tissues. As one of the leading causes of retinal vascular disease after diabetic retinopathy, RVO remains a major contributor to irreversible vision impairment globally, particularly among aging populations.
The disease is broadly categorized into Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO), and hemi-central Retinal Vein Occlusion (hemi-CRVO), depending on the location and extent of venous obstruction. Among these, CRVO is generally associated with more severe visual impairment and a higher risk of complications, including neovascular glaucoma and extensive retinal ischemia.
Retinal Vein Occlusion is closely linked to systemic conditions such as hypertension, diabetes mellitus, hyperlipidemia, glaucoma, and atherosclerosis. Increasing prevalence of cardiovascular and metabolic disorders worldwide has contributed significantly to the growing burden of RVO. Furthermore, rising life expectancy and expanding geriatric populations continue to elevate the incidence of retinal vascular diseases globally.
Clinically, patients with Retinal Vein Occlusion often present with sudden, painless blurring or loss of vision in one eye. Visual disturbances may range from mild impairment to severe vision loss depending on the degree of retinal involvement and presence of macular edema. Additional symptoms can include floaters, distorted vision, dark spots, or partial visual field defects. In ischemic forms of the disease, abrupt and profound vision loss may occur, requiring urgent ophthalmic intervention.
Diagnosis of RVO involves detailed ophthalmic examination combined with advanced retinal imaging techniques. Fundoscopic examination frequently reveals retinal hemorrhages, dilated tortuous veins, optic disc swelling, and cotton wool spots. Optical Coherence Tomography (OCT) plays a critical role in assessing retinal thickness and identifying fluid accumulation associated with macular edema. Fluorescein angiography further helps evaluate retinal perfusion, vascular leakage, and ischemic changes. Physicians may additionally conduct laboratory testing to identify systemic risk factors and underlying coagulation abnormalities.
Current treatment approaches for Retinal Vein Occlusion primarily focus on controlling macular edema, improving retinal perfusion, and preserving visual acuity. Intravitreal anti-VEGF therapies remain the standard of care and have significantly improved treatment outcomes over the last decade. However, limitations including frequent injections, treatment resistance, recurrence, and patient burden continue to drive demand for more durable and effective therapies.

Retinal Vein Occlusion Pipeline Landscape Witnesses Significant Innovation
The Retinal Vein Occlusion therapeutic market is experiencing rapid transformation, fueled by advancements in retinal imaging, biologic engineering, vascular stabilization technologies, and sustained ocular drug delivery systems. The pipeline increasingly emphasizes long-acting therapies capable of reducing injection frequency while maintaining durable efficacy and improved retinal outcomes.
Novel therapeutic strategies are targeting multiple disease pathways, including VEGF inhibition, vascular stabilization, anti-inflammatory modulation, neuroprotection, and ischemia reduction. The integration of bispecific antibodies, recombinant fusion proteins, and sustained-delivery platforms reflects the growing complexity and sophistication of ophthalmology drug development.

Gain deeper insights into the emerging Retinal Vein Occlusion clinical pipeline and innovation trends:
https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

According to DelveInsight's analysis, approximately 13+ companies are actively involved in the development of therapies for Retinal Vein Occlusion, collectively working on over 14 pipeline products spanning discovery, preclinical, Phase I, Phase II, and Phase III clinical stages. Several candidates are focused on improving durability and reducing treatment burden, which remain key unmet needs in retinal vascular disease management.
The report highlights growing strategic collaborations, acquisitions, licensing agreements, and funding activities across the ophthalmology sector. Pharmaceutical and biotechnology companies are increasingly investing in retinal vascular disorders due to rising disease prevalence, technological advancements in ocular therapeutics, and strong commercial potential associated with long-term vision preservation therapies.

Retinal Vein Occlusion Emerging Drugs Profile
Tarcocimab Tedromer: Kodiak Sciences
Tarcocimab tedromer is an investigational anti-VEGF therapy developed using Kodiak Sciences' proprietary Antibody Biopolymer Conjugate (ABC) platform technology. The therapy is specifically engineered to maintain sustained therapeutic concentrations within ocular tissues over extended durations, potentially reducing the frequency of intravitreal injections compared to currently available anti-VEGF agents.
The clinical development program for tarcocimab tedromer spans multiple retinal vascular disorders, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), non-proliferative diabetic retinopathy (NPDR), and Retinal Vein Occlusion. Clinical trials such as GLEAM, GLIMMER, DAYLIGHT, GLOW, and BEACON are evaluating the drug's efficacy, durability, and safety across these indications.
The BEACON study specifically focuses on patients with Retinal Vein Occlusion-associated macular edema. The therapy aims to provide extended treatment durability while maintaining visual acuity improvements and retinal fluid control. Tarcocimab tedromer is currently in Phase III clinical development and represents one of the most advanced pipeline therapies in the RVO space.

MK-8748: Merck
MK-8748 is a novel bispecific antibody being developed by Merck for the treatment of Retinal Vein Occlusion and other retinal vascular disorders. Engineered as a bi-functional Fc-fusion protein, MK-8748 simultaneously targets vascular leakage and angiogenic signaling pathways.
The therapy functions as both a TIE2 receptor agonist and VEGF antagonist. By activating TIE2-mediated vascular stabilization while inhibiting VEGF-driven angiogenesis, the therapy aims to improve retinal vascular integrity, reduce edema, and enhance visual outcomes beyond conventional anti-VEGF monotherapies.
The acquisition of EyeBio significantly strengthened Merck's ophthalmology portfolio and accelerated development of MK-8748. The drug is currently being evaluated in Phase II clinical trials for Retinal Vein Occlusion and has generated considerable interest due to its differentiated dual-mechanism approach.

ANXV: Annexin Pharmaceutical
ANXV is an investigational biologic therapy developed by Annexin Pharmaceutical targeting retinal vascular disorders associated with inflammation and vascular leakage. The therapy is designed to restore vascular integrity and protect retinal cells from inflammatory damage.
ANXV aims to address underlying vascular dysfunction contributing to retinal edema and ischemic complications in Retinal Vein Occlusion. The therapy is currently progressing through clinical development and represents a promising alternative strategy beyond traditional VEGF inhibition.

TH103: Kalaris Therapeutics
TH103 is an emerging retinal therapy under development by Kalaris Therapeutics for vascular retinal diseases including Retinal Vein Occlusion. The therapy is being investigated for its potential to provide improved durability, retinal stabilization, and enhanced patient convenience compared to existing treatment approaches.
Kalaris Therapeutics continues to expand its ophthalmology development programs through innovative biologic technologies and targeted retinal vascular interventions.

PER-001: Perfuse Therapeutics
PER-001 is an investigational therapy developed by Perfuse Therapeutics targeting retinal ischemia and vascular dysfunction. Unlike conventional therapies focused solely on edema reduction, PER-001 aims to improve retinal perfusion and oxygen delivery, potentially addressing broader disease mechanisms associated with RVO progression.
The therapy reflects growing interest in retinal ischemia-focused treatment approaches capable of improving long-term retinal health and visual function.

Retinal Vein Occlusion Pipeline Segmentation and Therapeutic Assessment
DelveInsight's report provides comprehensive segmentation of pipeline candidates based on clinical stage, route of administration, molecule type, and product classification.
Retinal Vein Occlusion Clinical Trial Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Preclinical candidates
• Discovery-stage therapies
• Inactive and discontinued programs

Retinal Vein Occlusion Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Retinal Vein Occlusion Molecule Types
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Retinal Vein Occlusion Product Types
• Mono therapies
• Combination therapies
• Mono/Combination products
These diverse development strategies underscore the growing complexity of retinal vascular disease treatment and the industry's continued efforts to address unmet clinical needs through innovative therapeutic modalities.

Access comprehensive pipeline segmentation, clinical trial analysis, and company benchmarking insights here: https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Clinical Trial and Development Activities Accelerating Market Growth
The Retinal Vein Occlusion pipeline is characterized by increasing clinical trial activity and expanding investments in ophthalmology innovation. Pharmaceutical companies and emerging biotechnology firms are aggressively pursuing next-generation retinal therapies with enhanced durability, efficacy, and safety profiles.
Collaborations between industry and academia are playing a critical role in advancing retinal vascular research. Strategic acquisitions and licensing agreements are also reshaping the competitive landscape, allowing larger pharmaceutical companies to strengthen ophthalmology portfolios and accelerate commercialization timelines.
Companies such as Kodiak Sciences and Merck are leading the development of advanced biologic therapies, while smaller innovators including Perfuse Therapeutics and PulseSight Therapeutics are exploring differentiated approaches targeting retinal perfusion, vascular repair, and inflammatory pathways.
The increasing use of artificial intelligence-enabled imaging analytics and precision ophthalmology technologies is further expected to optimize patient selection, disease monitoring, and treatment response evaluation in future clinical trials.

Retinal Vein Occlusion Market Drivers, Challenges, and Future Outlook
Several factors are contributing to the growing momentum within the Retinal Vein Occlusion pipeline market. Rising prevalence of diabetes, hypertension, cardiovascular diseases, and aging-related retinal disorders continues to expand the patient population requiring long-term ophthalmic care.
Increased awareness regarding retinal diseases, advancements in retinal imaging diagnostics, and expanding healthcare access are supporting earlier diagnosis and treatment intervention. Furthermore, the commercial success of anti-VEGF therapies has validated the strong market potential for retinal vascular disease therapeutics.
However, significant challenges remain within the RVO treatment landscape. Frequent intravitreal injections continue to create substantial burden for patients and healthcare systems. Variability in therapeutic response, recurrence of macular edema, and limited long-term disease modification also highlight ongoing unmet needs.
Future therapeutic innovation is expected to focus on durable delivery systems, multi-target biologics, retinal regeneration technologies, and personalized ophthalmic medicine. Emerging gene therapies and ischemia-targeted treatments may further transform future disease management approaches.
As pipeline candidates continue progressing through clinical development, the Retinal Vein Occlusion market is anticipated to witness substantial evolution over the coming decade, with next-generation therapies potentially redefining standards of retinal vascular care worldwide.

Discover complete Retinal Vein Occlusion pipeline intelligence, emerging therapies, and future market forecasts: https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Retinal Vein Occlusion Pipeline Report
• Coverage: Global
• Key Companies: Kodiak Sciences, Merck, Annexin Pharmaceutical, Kalaris Therapeutics, Perfuse Therapeutics, PulseSight Therapeutics, and others
• Key Therapies: Tarcocimab tedromer, MK-8748, ANXV, TH103, PER-001, PST 809
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Table of Contents
1. Introduction
2. Executive Summary
3. Retinal Vein Occlusion Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.